Literature DB >> 11246662

Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens.

M W van der Linden1, R G Westendorp, M Zidane, L Meheus, T W Huizinga.   

Abstract

OBJECTIVE: The presence of antinuclear autoantibodies in systemic lupus erythematosus (SLE) is influenced by genetic factors. The presence of autoantibodies in healthy family members of patients has been reported. Our hypothesis was that autoantibodies are directed against the same antigens in first-degree family members of patients with SLE as in their patient relative.
METHODS: Plasma was harvested from 50 patients with SLE, 154 unaffected first-degree family members, and 330 healthy controls. Presence of autoantibodies against 14 specific nuclear antigens was tested by the ELISA based line immunoassay INNO-LIA method.
RESULTS: Seventy-four percent of patients, 32% of first-degree family members, and 1.5% of healthy controls had antibodies against any nuclear antigen. Most frequent autoantibodies in the patients were anti-histone and anti-SSA, whereas in the family members these were anti-RNP-C and anti-Topo-I/Scl. Presence and specificity of autoantibodies in family members were independent of the presence or absence of that autoantibody in their patient relative (chi-square p > 0.1 for all 14 antigens).
CONCLUSION: Autoantibodies in family members and their patient relatives are not directed against the same nuclear antigens. Thus a familial aspecific dysfunction of the B lymphocyte is the most likely explanation for autoantibody production in SLE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246662

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Shared autoimmunity: the time has come.

Authors:  Donato Alarcón-Segovia
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

2.  Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes.

Authors:  Q-Z Li; J Zhou; A E Wandstrat; F Carr-Johnson; V Branch; D R Karp; C Mohan; E K Wakeland; N J Olsen
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

3.  Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.

Authors:  Melissa E Munroe; Kendra A Young; Diane L Kamen; Joel M Guthridge; Timothy B Niewold; Karen H Costenbader; Michael H Weisman; Mariko L Ishimori; Daniel J Wallace; Gary S Gilkeson; David R Karp; John B Harley; Jill M Norris; Judith A James
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

4.  Compensatory T-cell regulation in unaffected relatives of SLE patients, and opposite IL-2/CD25-mediated effects suggested by coreferentiality modeling.

Authors:  Constantin Fesel; Marta Barreto; Ricardo C Ferreira; Nuno Costa; Lara L Venda; Clara Pereira; Claudia Carvalho; Maria Francisca Morães-Fontes; Carlos M Ferreira; Carlos Vasconcelos; João F Viana; Eugenia Santos; Berta Martins; Jocelyne Demengeot; Astrid M Vicente
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

5.  Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients.

Authors:  Judith A James; Hua Chen; Kendra A Young; Elizabeth A Bemis; Jennifer Seifert; Rebecka L Bourn; Kevin D Deane; M Kristen Demoruelle; Marie Feser; James R O'Dell; Michael H Weisman; Richard M Keating; Patrick M Gaffney; Jennifer A Kelly; Carl D Langefeld; John B Harley; William Robinson; David A Hafler; Kevin C O'Connor; Jane Buckner; Joel M Guthridge; Jill M Norris; V Michael Holers
Journal:  EBioMedicine       Date:  2019-04-03       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.